Form 4: Champions Oncology Director Exercises Options, Reports Changes in Beneficial Ownership

Joel Ackerman, a director at Champions Oncology, Inc., reports exercising options to purchase common stock at prices of $2.1 and $5.43, resulting in adjustments to his beneficial ownership.

Summary

• On October 31, 2024, Joel Ackerman, a director of Champions Oncology, Inc., exercised options to purchase 88,470 shares of common stock at $2.1 per share.
• Ackerman also exercised options to purchase 16,667 shares of common stock at $5.43 per share on the same date.
• Following these transactions, Ackerman's directly held beneficial ownership of common stock increased to 962,134 shares.
• Ackerman now holds zero options to purchase common stock at both $2.1 and $5.43.
• The options for 88,470 shares were granted on July 19, 2016, and were immediately exercisable.
• The options for 16,667 shares had a vesting schedule starting November 4, 2019, with the remaining options vesting on subsequent dates in 2020.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing insider transactions. The exercise of options could be seen as a positive signal, but it's not definitively indicative of strong positive or negative sentiment.

Positives

• Director Ackerman's exercise of options could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in the number of outstanding shares.

Key Dates